Evogene Ltd. EVGN

Healthcare SIC 2870 - Agricultural Chemicals NAICS Manufacturing › Chemical Manufacturing › Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing › Fertilizer and Compost Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.9M$5.6M$3.0M$1.7M$930.0K$1.0M$753.0K$1.7M$3.4M$6.5M
Operating income -$14.0M-$18.8M-$22.2M-$26.9M-$31.0M-$24.8M-$21.2M-$20.0M-$21.9M-$21.1M
Net income -$7.8M-$18.1M-$26.0M-$29.8M-$30.4M-$26.2M-$19.1M-$20.8M-$20.8M-$19.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $20.0M$39.9M$51.1M$56.1M$76.3M$71.9M$71.4M$58.7M$77.6M$96.0M
Total equity $12.0M$14.8M$28.7M$34.8M$63.4M$56.9M$60.2M$50.3M$69.4M$87.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001767.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -30M -20M -10M 0 10M Revenue, FY2016: 6.5M Net income, FY2016: -19.6M Revenue, FY2017: 3.4M Net income, FY2017: -20.8M Revenue, FY2018: 1.7M Net income, FY2018: -20.8M Revenue, FY2019: 753K Net income, FY2019: -19.1M Revenue, FY2020: 1M Net income, FY2020: -26.2M Revenue, FY2021: 930K Net income, FY2021: -30.4M Revenue, FY2022: 1.7M Net income, FY2022: -29.8M Revenue, FY2023: 3M Net income, FY2023: -26M Revenue, FY2024: 5.6M Net income, FY2024: -18.1M Revenue, FY2025: 3.9M Net income, FY2025: -7.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $6.5M $3.4M $1.7M $753.0K $1.0M $930.0K $1.7M $3.0M $5.6M $3.9M
Gross profit — — — — — — — — — —
Net income -$19.6M -$20.8M -$20.8M -$19.1M -$26.2M -$30.4M -$29.8M -$26.0M -$18.1M -$7.8M

Others in SIC 2870

TickerCompanyMarket capP/ERevenue growth
CF CF Industries Holdings, Inc. $18.26B 13.5x 19.3%
MOS MOSAIC CO $5.67B 10.5x 8.4%
SMG SCOTTS MIRACLE-GRO CO $3.45B 24.0x -3.9%
UAN CVR PARTNERS, LP $1.33B 13.4x 15.4%
CBUS Cibus, Inc. $108.2M — -14.6%
AVD AMERICAN VANGUARD CORP $30.4M — -5.9%
SNES SenesTech, Inc. $4.6M — 19.6%
BIOX Bioceres Crop Solutions Corp. — — -27.9%